期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

非小细胞肺癌个体化治疗相关分子标记物 被引量：8

The Molecular Markers Related to Personalized Therapy of Non-small Cell Lung Cancer
下载PDF
导出
摘要 肺癌是人类发病率和死亡率最高的恶性肿瘤,全世界每年肺癌发生超过150万例,我国是肺癌的高发国家之一。2009年美国临床肿瘤学会（American Society of Clinical Oncology,ASCO）年会提出了＂肿瘤个体化治疗,让癌症患者活得更长、活得更好＂的主题,
作者 郭楠楠 尉承泽 于长海
机构地区 解放军总医院第一附属医院心胸外科 军事医学科学院
出处 《中国肺癌杂志》 CAS 2011年第3期292-296,共5页 Chinese Journal of Lung Cancer
关键词 非小细胞肺癌 个体化治疗 分子标记物 美国临床肿瘤学会 恶性肿瘤 2009年 癌症患者 死亡率
分类号 R734.2 [医药卫生—肿瘤]
  • 相关文献

参考文献32

  • 1Molinari A,alcabrini A, Meschini S, et al. Detection of P-glycoprotein. Int JCancer, 1998, 75(6): 885-893.
  • 2Shapiro AB, Fox K, Lee P, et al, Functional intracellular P-glycoprotein. Int J Cancer, 1998, 76(6): 857-864.
  • 3RaezLE, Lilenbaum R. New developments in chemotherapy for advanced non-small cell lung cancer. Curt Opin Oncol, 2006, 18(2): 156.
  • 4EismannU, Oberschmidt O, Ehnert M, et al. Thymidylate synthase gene expression in solid tumors predicts for response to Pemetrexed in vitro. J CIin Oncol, 2006, 24(Suppl): 13058.
  • 5Bepler G, Shama S, CantorA, et al. RRM1 and PTEN as prognostic parameters for overall and diseasefree survival in patients with non-smallcell lung cancer.J Clin Oncol, 2004, 22(10): 1878-1885.
  • 6Davidson JD, MaL, Flagella M, et al. Anincrease in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines. Cancer Res, 2004, 64(11): 3761-3766.
  • 7Zheng Z, Chen T, Li X, et al. DNA synthesis and repair genes RRN1 and ERCC1 in lung cancer. N EnglJ Med, 2007, 356(8): 800-808.
  • 8Scagliotti GV, De Marinis F, Ri-naldi M, et al. PhaseⅢ randomized trial comparing three platinumbased doublets in advanced non-small-cell lung cancer. Clin Oncol, 2002, 20(21): 4285-4291.
  • 9Giannakakou P, Gussio R, Nogales E, et al. A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin-mutations in human cancer cells. Proc Natl Acad Sci USA, 2000, 97(2000): 2904-2909.
  • 10Rosell R, Felip E. Predicting response to paclitaxel/carboplatin-based therapy in non-small cell lung ancer. Semin Oncol, 2001, 28(4 Suppi 14): 37-44.

同被引文献129

  • 1靳毅,刘巍.索拉非尼治疗非小细胞肺癌的临床研究进展[J].肿瘤,2010,30(9):795-797. 被引量：6
  • 2郑淑君,叶晓青,李思勤,林芳宇,成守珍,陈维清.住院患者健康教育需求及教育成效影响因素的调查[J].解放军护理杂志,2007,24(1):24-26. 被引量：27
  • 3Jemal A, Siegel R, Xu J, et al. Cancer statistics 2010. CA Cancer J Clin, 2010, 60:277-300.
  • 4Gridelli C, Maione P, Rossi A, et al. Chemotherapy of advanced NSCLC in special patient population. Ann Oncol, 2006, 17 Suppl 5 : v72-75.
  • 5Geridelli C, Shepherd FA. Chernotherpay for elderly patients with non-small cell lung caneer: a review of the evidence. Chest, 2005, 128:947-957.
  • 6Dacic S. Molecular diagnostics of lung carcinomas. Arch Pathol Lab Med, 2011, 135:622-629.
  • 7Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin- paelitaxel in pulmonary adenocarcinoma. N Engl J Med, 2009, 361:947-957.
  • 8Maione P, Rossi A, Sacco PC, et al. Treating advanced non- small cell lung cancer in the elderly. Ther Adv Med Oncol, 2010, 2:251-260.
  • 9Zhang L, Yang H, Xu J. Gene expression significance i personalized medicine of non-small-cell lung cancer and gent expression analyzing platforms. CmT Drug Metab, 2011, 12:455] 459. /.
  • 10Cobo M, Isla D, Massuti B, et al. Customizing eisplatin based on quantitative exeision repair cross-complementing 1 mRNA expression: a phase ]]I trial in non-small-ee|l lung cancer. J Clin Oneol, 2007, 25:2747-2754.

引证文献8

二级引证文献46

中国肺癌杂志
2011年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部